title: Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
authors.forename: Frederick W
authors.initials: FW
authors.lastname: Fraunfelder
authors.forename: Kevin
authors.initials: K
authors.lastname: Winthrop
authors.forename: Eric
authors.initials: E
authors.lastname: Suhler
authors.forename: Dongseok
authors.initials: D
authors.lastname: Choi
authors.forename: Frederick T
authors.initials: FT
authors.lastname: Fraunfelder
mesh_terms: D000284:Administration, Oral; D019386:Alendronate / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D016208:Databases, Factual; D004164:Diphosphonates; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D006801:Humans; D007263:Infusions, Parenteral; D000077268:Pamidronate; D010607:Pharmacy Service, Hospital / Q000706:statistics & numerical data; D011358:Product Surveillance, Postmarketing / Q000706:statistics & numerical data*; D015423:Scleritis / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D014481:United States; D014493:United States Department of Veterans Affairs / Q000706:statistics & numerical data*; D014605:Uveitis / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D014728:Veterans / Q000706:statistics & numerical data
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate; D019386:Alendronate